A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Status:
RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.